

Chronic Pancreatitis - Pipeline Insight, 2021

<https://marketpublishers.com/r/CC49A2DCC4A9EN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CC49A2DCC4A9EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Chronic Pancreatitis - Pipeline Insight, 2021," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Pancreatitis Understanding

Chronic Pancreatitis: Overview

Chronic pancreatitis is commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes. Symptoms of chronic pancreatitis range widely and may include vomiting, constant dull, unremitting abdominal pain, epigastric tenderness, weight loss, steatorrhea and glucose intolerance. Chronic pancreatitis is usually a complication of recurrent episodes of acute pancreatitis. Diagnosis of chronic pancreatitis is based on medical history, physical examination, and through various tests like imaging tests, endoscopic retrograde cholangiopancreatography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography. Treatment for chronic pancreatitis includes medical, endoscopic and surgical therapy. Pancreatic enzyme supplementation may be helpful in

reducing pain.

'Chronic Pancreatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pancreatitis pipeline landscape is provided which includes the disease overview and Chronic Pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pancreatitis.

Chronic Pancreatitis Emerging Drugs Chapters

This segment of the Chronic Pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Pancreatitis Emerging Drugs

Oral CRAC channel inhibitors: CalciMedica

CalciMedica is developing oral CRAC channel inhibitors for chronic indications treated in an outpatient setting. The drug is in pre-clinical studies for the treatment of Chronic Pancreatitis.

NI-03: Kangen Pharmaceuticals

NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity. The drug is in Phase I/II clinical studies for the treatment of Chronic Pancreatitis. The drug has been approved in Japan but has not been approved in the United States.

Further product details are provided in the report.....

Chronic Pancreatitis: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Pancreatitis

There are approx. 6+ key companies which are developing the therapies for Chronic Pancreatitis. The companies which have their Chronic Pancreatitis drug candidates in the most advanced stage, i.e. Phase II include, AzurRx.

Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic Pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Pancreatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Pancreatitis therapeutic drugs

key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pancreatitis drugs.

Chronic Pancreatitis Report Insights

Chronic Pancreatitis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic Pancreatitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Pancreatitis drugs?

How many Chronic Pancreatitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pancreatitis?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Pancreatitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic Pancreatitis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

CalciMedica

GNT Pharma

Koligo Therapeutics

Kangen Pharmaceuticals

AzurRx SAS

Theraly Fibrosis

Key Products

Oral CRAC inhibitor

Flusalazine

KT CP 203

NI-03

MS1819-SD

TLY012

Contents

Introduction

Executive Summary

Chronic Pancreatitis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Chronic Pancreatitis – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

MS1819-SD: AzurRx SAS

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Flusalazine: GNT Pharma

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical/Discovery Stage Products
 Comparative Analysis
Oral CRAC inhibitor: CalciMedica
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Chronic Pancreatitis Key Companies
Chronic Pancreatitis Key Products
Chronic Pancreatitis- Unmet Needs
Chronic Pancreatitis- Market Drivers and Barriers
Chronic Pancreatitis- Future Perspectives and Conclusion
Chronic Pancreatitis Analyst Views
Chronic Pancreatitis Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Chronic Pancreatitis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Chronic Pancreatitis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Chronic Pancreatitis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CC49A2DCC4A9EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC49A2DCC4A9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970